Kolexia
Frenel Jean-Sebastien Oncologie médicale
Frenel Jean-Sebastien
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
383 Activités
455 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Glioblastome Tumeurs de l'ovaire Récidive tumorale locale Tumeurs du cerveau Métastase tumorale Carcinomes Carcinome épithélial de l'ovaire Tumeurs de l'endomètre

Collaborateurs

Voir plus
Campone Mario
Campone Mario
Ico - Site Paul Papin, Angers, France
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
AstraZeneca
17 collaboration(s)
Dernière en 2023
Seagen
14 collaboration(s)
Dernière en 2023
CanceroDigest
13 collaboration(s)
Dernière en 2023
Pfizer
12 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE): A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Essai Clinique (PMV Pharmaceuticals, Inc)   07 février 2024
62P Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed glioblastoma multiforme: PAZOGLIO trial
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   19 janvier 2024
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Essai Clinique (Daiichi Sankyo)   17 janvier 2024
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Étude NATALEE : ribociclib + HT adjuvante dans les cancers du sein RH+/HER2− de stade 2 et 3
Edimark   01 décembre 2023